Results 41 to 50 of about 692,682 (292)

Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes [PDF]

, 2001
Aims: To assess satisfaction with treatment and psychological well-being associated with insulin glargine and NPH. Insulin glargine, a new long-acting insulin analogue, provides constant, peakless insulin release following once-daily administration and ...
Bradley, Clare, Stewart, J, Witthaus, E
core   +1 more source

Effect of insulin glargine on cardiovascular risk analysed by mean HRV [PDF]

, 2019
Type 2 diabetes mellitus is an insidious disease that is increasingly present in geriatric population [1]. The greatest difficulty is represented by glycaemic control in geriatric patients often not very compliant with diet therapy and drug therapy.
Apicella, G., Dalmaso, S., Marchitto, N., Marcinnò, M., Petrucci, A., Raimondi, G.   +5 more
core   +1 more source

ANALISIS EFEKTIVITAS BIAYA MEDIS LANGSUNG PENGGUNAAN INSULIN DAN INSULIN KOMBINASI OHO PADA PASIEN DM TIPE 2 RAWAT JALAN DI RSUP SANGLAH DENPASAR

Jurnal Ilmiah Medicamento, 2018
Diabetes Melitus merupakan penyakit kronis dimana terapi pengobatannya dilakukan seumur hidup dan membutuhkan biaya yang sangat besar. Bervariasinya penggunaan terapi insulin atau kombinasi insulin dengan OHO (Obat Hipoglikemik Oral) pada pasien DM tipe
Ni Nyoman Wahyu Udayani, Herleeyana Meriyani, I Gusti Agung Ayu Kusuma Wardani   +2 more
doaj   +3 more sources

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

Cardiovascular Diabetology, 2008
Objective Exenatide belongs to a new therapeutic class in the treatment of diabetes (incretin mimetics), allowing glucose-dependent glycaemic control in Type 2 diabetes.
Tetlow Anthony P, Evans Mark, Woehl Anette, McEwan Philip   +3 more
doaj   +1 more source

Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin [PDF]

, 2011
Aims/hypothesis Several publications suggest an association between certain types of insulin and cancer, but with conflicting results. We investigated whether insulin glargine (A21Gly,B31Arg,B32Arg human insulin) is associated with an increased risk of ...
A Dejgaard, AS Fauci, B. H. Ch. Stricker, BH Stricker, CH Chang, CJ Currie, D Mayer, D Mayer, D Simon, E Friberg, E Giovannucci, E Mannucci, Emerging Risk Factors Collaboration, H. R. Haak, HC Gerstein, HM Colhoun, J Rosenstock, J. W. W. Coebergh, JA Johnson, JM Jonasson, K Rothman, KL Edwards, L. E. Visser, LG Hemkens, LV Poll-Franse van de, M. P. P. van Herk-Sukel, MM Hassan, N Morden, P Kurtzhals, P Vigneri, P. H. Geelhoed-Duijvestijn, PD Home, R Huxley, R. M. C. Herings, R. Ruiter, S Bonovas, S Hernandez-Diaz, S Suissa, S. M. J. M. Straus, SC Larsson, SC Larsson, SC Larsson, SE Kahn, SJ Pocock, SL Bowker, SS Coughlin, U Smith, VA Grote, X Yang, YX Yang   +49 more
core   +5 more sources

Insulin glargine use and breast cancer: a systematic review and meta-analysis

Electronic Physician, 2019
Background: Insulin is widely used in the treatment of diabetes. There is an increasing concern regarding the association between insulin glargine use and breast cancer.
Ibrahim Altedlawi Albalawi, Hyder Osman Mirghani   +1 more
doaj   +1 more source

The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3 [PDF]

, 2018
Aims To evaluate the effect of concomitant dipeptidyl peptidase IV inhibitor (DPPIVi) use on efficacy and safety of insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in people with type 2 diabetes on oral antihyperglycaemic drugs ...
Brito-Sanfiel, Miguel, Buzzetti, Raffaella, Chevalier, Soazig, Lavalle-Gonzalez, Fernando, Merino-Trigo, Ana, Pettus, Jeremy Hodson, Stella, Peter, Yale, Jean-François   +7 more
core   +4 more sources

Special aspects of concentrated insulins: basic characteristics and research findings

Сахарный диабет, 2019
The appearance of concentrated insulins in clinical practice determines the need to analyze product priorities in appropriate groups of patients with diabetes. The aim of this article is to summarize the literature on concentrated insulins (i.e.
Tatiana Y. Demidova, Olga V. Balutina
doaj   +1 more source

Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis

Cost Effectiveness and Resource Allocation, 2019
Background International guidelines recommend using basal insulin in patients with type-2 diabetes mellitus if glycaemic target cannot be attained on non-insulin anti-diabetic drugs.
E. Lau, A. Salem, J. C. N. Chan, W. Y. So, A. Kong, M. Lamotte, A. Luk   +6 more
doaj   +1 more source

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

Diabetologia, 2020
Aims/hypothesis A head-to-head randomised trial was conducted to evaluate hypoglycaemia safety with insulin degludec 200 U/ml (degludec U200) and insulin glargine 300 U/ml (glargine U300) in individuals with type 2 diabetes treated with basal insulin ...
A. Philis-Tsimikas, D. Klonoff, K. Khunti, H. Bajaj, Lawrence A Leiter, M. V. Hansen, L. Troelsen, S. Ladelund, S. Heller, T. Pieber   +9 more
semanticscholar   +1 more source